EICHORCondition: DPMAS Therapy in Liver Disease Patients · Sponsor: Nanfang Hospital, Southern Medical University
Acute-on-chronic liver failure (ACLF) is a life-threatening syndrome occurring in patients with chronic liver disease. In China, hepatitis B virus (HBV) is the main cause of cirrhosis. HBV related ACLF is characterized by multiple organs failure (liver, coagulation and kidney, etc.) and confers with high risk of short-term mortality. For the treatment of ACLF patients, recent studies have explored the therapeutic efficacy of extracorporeal liver support therapies, such as albumin dialysis, plasma exchange. However, the clinical efficacy remains to be fully elucidated. Liver transplantation is the most efficient way to improve the survival of ACLF patients, especially for those suffering from three or more organ failures. Recently, a novel extracorporeal system which is called double plasma molecular adsorption system (DPMAS) has been applied for the treatment of ACLF patients. DPMAS is an extracorporeal therapeutic procedure that combines two hemoperfusion devices. During treatment, toxic plasma is isolated and purified via perfusion through two adsorbers, after which the purified plasma is reinfused back into the patient's circulation. This technique requires no massive plasma supply and avoids the risks of plasma-related allergic reactions and pathogen transmission. DPMAS can rapidly alleviate jaundice and lower serum bilirubin levels, thereby mitigating the hepatotoxic effects induced by excessive bilirubin and bile acids. Despite the widespread clinical application of DP…
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| The Second Affiliated Hospital of Chongqing Medical University | Chongqing, Chongqing Municipality, China | — |
| Nanfang Hospital | Guangzhou, Guangdong, China | — |
| The Third Hospital of Hebei Medical University | Hebei, Hebei, China | — |
| Hunan Provincial People's Hospital | Changsha, Hunan, China | — |
| Xiangya Hospital of Central South University | Changsha, Hunan, China | — |
| Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School | Nanjing, Jiangsu, China | — |
| The Affiliated Hospital of Xuzhou Medical University | Xuzhou, Jiangsu, China | — |
| The First Affiliated Hospital of Nanchang University | Nanchang, Jiangxi, China | — |
| The Second Affiliated Hospital Of Nanchang University | Nanchang, Jiangxi, China | — |
| The First Hospital of Jilin University | Changchun, Jilin, China | — |
| Qilu Hospital of Shandong University | Jinan, Shandong, China | — |
| Shandong Provincial Clinical Center for Public Health | Jinan, Shandong, China | — |
+ 44 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05129904